India - English - Central Drugs Standard Control Organization

bienstar - amoxycillin,clavulanic acid - tab - 500,125;mg - 6

India - English - Central Drugs Standard Control Organization

pharma synth - cap - 10

India - English - Central Drugs Standard Control Organization

pharma synth - syr - 200ml

India - English - Central Drugs Standard Control Organization

pharma synth - dps - 20ml

United States - English - NLM (National Library of Medicine)

aspen veterinary resources, ltd. - each fluid ounce (2 tablespoons) contains:, kaolin ................ 90 gr. (5.8 g), pectin ................ 2 gr. (0.13 g), inactive ingredients, in a palatable vehicle. flavorings and color added. - anti-diarrheal liquid for animal use only keep out of reach of children restricted drug.  use only as directed. not for human use. indications for oral administration as an aid in the treatment of noninfectious diarrhea in horses, cattle, dogs and cats.

United States - English - NLM (National Library of Medicine)

durvet, inc. - each fluid ounce contains, kaolin (colloidal) ................................ 90 gr., pectin (citrus) ..................................... 2 gr., in a palatable vehicle. flavorings and color added. - kaolin 5.8 g in 29.57 ml - anti-diarrheal liquid for animal use only keep out of reach of children indications a palatable oral suspension for use in controlling simple diarrhea in horses, cattle, dogs and cats.

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - polyethylene glycol 3350 420 g in 438.4 g - gavilyte-n is indicated for bowel cleansing prior to colonoscopy in adults and pediatric patients aged 6 months or greater. gavilyte-n is contraindicated in the following conditions: - gastrointestinal (gi) obstruction, ileus, or gastric retention - bowel perforation - toxic colitis or toxic megacolon - known allergy or hypersensitivity to any component of gavilyte-n for oral solution [see how supplied/storage and handling (16)] animal reproduction studies have not been conducted with gavilyte-n. it is also not known whether gavilyte-n can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. gavilyte-n should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when gavilyte-n is administered to a nursing woman. safety and effectiveness of gavilyte-n in pediatric patients aged 6 months and older is supported by evidence from adequate and well-controlled clinical trials of gavilyte-n in adults with additional safety and efficacy data from published studies of similar formulations. use of gavilyte-n in children younger than 2 years of age should be carefully monitored for occurrence of possible hypoglycemia, as this solution has no caloric substrate. dehydration has been reported in one child and hypokalemia has been reported in 3 children. clinical studies of gavilyte-n did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients.

United States - English - NLM (National Library of Medicine)

braintree laboratories, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - polyethylene glycol 3350 420 g in 4 l - nulytely is indicated for bowel cleansing prior to colonoscopy in adults and pediatric patients aged 6 months or greater. nulytely is contraindicated in the following conditions: - gastrointestinal (gi) obstruction, ileus, or gastric retention - bowel perforation - toxic colitis or toxic megacolon - known allergy or hypersensitivity to any component of nulytely [ see how supplied/storage and handling ( 16) ] pregnancy category c. animal reproduction studies have not been conducted with nulytely. it is also not known whether nulytely can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. nulytely should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when nulytely is administered to a nursing woman. safety and effectiveness of nulyte

United States - English - NLM (National Library of Medicine)

wallace pharmaceuticals inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - polyethylene glycol 3350 420 g in 4 l - trilyte is indicated for bowel cleansing prior to colonoscopy in adults and pediatric patients aged 6 months or greater. trilyte is contraindicated in the following conditions: animal reproduction studies have not been conducted with trilyte. it is also not known whether trilyte can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. trilyte should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when trilyte is administered to a nursing woman. safety and effectiveness of trilyte in pediatric patients aged 6 months and older is supported by evidence from adequate and well-controlled clinical trials of trilyte in adults with additional safety and efficacy data from published studies of similar formulations. use of trilyte in children younger than 2 years of age should be carefully monitored for occurrence of possible hypoglycemia, as

United States - English - NLM (National Library of Medicine)

affordable pharmaceuticals, llc - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - peg-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution is indicated for bowel cleansing prior to colonoscopy in adults and pediatric patients aged 6 months or greater. peg-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution is contraindicated in the following conditions: - gastrointestinal (gi) obstruction, ileus, or gastric retention - bowel perforation - toxic colitis or toxic megacolon - known allergy or hypersensitivity to any component of peg-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution [see how supplied/storage and handling (16) ] pregnancy category c. animal reproduction studies have not been conducted with peg-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution. it is also not known whether peg-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. p